CTOs on the Move


 
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.imaratx.com
  • 116 Huntington Avenue 6th Floor
    Boston, MA USA 02116
  • Phone: 617.206.2020

Executives

Name Title Contact Details

Funding

Imara raised $63M on 03/18/2019

Similar Companies

Bio-Circle

Bio-Circle is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Certus International Inc

Certus International Inc is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VIRxSYS Corporation

VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IDx Technologies

IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare.

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.